The syngo Virtual Cockpit platform reportedly enables remote access and image acquisition for CT, MRI and positron emission tomography (PET), and facilitates clinician collaboration across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may help facilitate improved access to advanced imaging for patients in remote locations.
The syngo Virtual Cockpit enables remote access for computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission CT (SPECT) imaging, according to Siemens Healthineers, the manufacturer of the software. The company said the remote platform also features live video and chat functionalities to foster collaboration between clinicians across multiple sites.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the syngo Virtual Cockpit, a multi-vendor remote scanning platform that may enable access to MRI, CT and positron emission tomography (PET) imaging for patients in remote locations.
In addition to possibly facilitating improved standardization for imaging of remote patients, Siemens Healthineers suggested the syngo Virtual Cockpit could be utilized in training staff at remote facilities.
“This FDA clearance means that our customers can use syngo Virtual Cockpit for their remote scanning operations with even more confidence that they are using a proven solution — one that prioritizes patient safety and convenience while also addressing operational and staffing challenges,” noted Peter Shen, head of digital and automation at Siemens Healthineers North America.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.